Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Update

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) was the target of a significant decline in short interest in March. As of March 31st, there was short interest totalling 3,660,000 shares, a decline of 17.6% from the March 15th total of 4,440,000 shares. Currently, 10.6% of the company’s stock are short sold. Based on an average trading volume of 426,500 shares, the days-to-cover ratio is presently 8.6 days.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on YMAB. Wedbush reiterated an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. HC Wainwright dropped their price objective on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Bank of America dropped their price target on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. Morgan Stanley lowered their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research note on Wednesday, March 5th. Finally, Truist Financial dropped their price objective on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.30.

Y-mAbs Therapeutics Stock Performance

YMAB stock opened at $4.69 on Friday. The company has a market cap of $212.07 million, a P/E ratio of -8.69 and a beta of 0.71. The stock’s 50 day simple moving average is $5.06 and its 200 day simple moving average is $8.48. Y-mAbs Therapeutics has a fifty-two week low of $3.86 and a fifty-two week high of $17.78.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. During the same quarter in the previous year, the company posted ($0.02) EPS. Equities analysts predict that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Thomas Gad sold 10,810 shares of the firm’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares of the company’s stock, valued at approximately $1,060,230.83. This trade represents a 5.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 22.50% of the company’s stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Institutional investors have recently made changes to their positions in the business. KLP Kapitalforvaltning AS acquired a new position in shares of Y-mAbs Therapeutics in the fourth quarter valued at approximately $46,000. ProShare Advisors LLC purchased a new position in Y-mAbs Therapeutics during the 4th quarter valued at about $99,000. Wells Fargo & Company MN lifted its position in shares of Y-mAbs Therapeutics by 54.1% in the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock valued at $137,000 after acquiring an additional 6,131 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Y-mAbs Therapeutics by 30.7% in the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock valued at $139,000 after purchasing an additional 4,163 shares in the last quarter. Finally, Principal Financial Group Inc. acquired a new position in Y-mAbs Therapeutics in the 3rd quarter valued at $267,000. Institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.